Effect of a Dual Orexin Receptor Antagonist on CSF Alzheimer's Disease Biomarkers
Latest Information Update: 29 Nov 2024
At a glance
- Drugs Lemborexant (Primary)
- Indications Alzheimer's disease
- Focus Biomarker; Therapeutic Use
Most Recent Events
- 12 Mar 2024 Planned End Date changed from 1 Feb 2031 to 11 Mar 2029.
- 12 Mar 2024 Planned primary completion date changed from 1 Feb 2029 to 11 Mar 2029.
- 04 Mar 2024 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Mar 2024 to 11 Mar 2024.